The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Degenerative Disc Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Degenerative Disc Disease Market.
Some of the key takeaways from the Degenerative Disc Disease Pipeline Report:
Companies across the globe are diligently working toward developing novel Degenerative Disc Disease treatment therapies with a considerable amount of success over the years.
Degenerative Disc Disease companies working in the treatment market are Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia Biopharmaceuticals, and others, are developing therapies for the Degenerative Disc Disease treatment
Emerging Degenerative Disc Disease therapies in the different phases of clinical trials are- SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and others are expected to have a significant impact on the Degenerative Disc Disease market in the coming years.
In March 2025, Discure Technologies, a clinical-stage medical device company developing innovative treatments for degenerative disc disease and other orthopedic conditions, has announced its acceptance into the U.S. Food and Drug Administration’s (FDA) Total Product Life Cycle (TPLC) Advisory Program (TAP). This inclusion is expected to accelerate patient access to the Discure System, the company’s bioelectronic implant, which had earlier been granted Breakthrough Device designation by the FDA.
In September 2024, Spine BioPharma, Inc., a development-stage company focused on non-opioid, non-surgical treatments for Degenerative Disc Disease (DDD), has announced the completion of patient enrollment for its U.S. Phase 3 clinical trial of SB-01 For Injection (SB-01). The Phase 3 MODEL trial (MOderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine) enrolled 417 patients over two years at 30 research sites across the U.S. SB-01 is the first intradiscal pharmacologic therapy to advance to Phase 3 trials for the treatment of chronic low back pain (CLBP) and the related loss of function caused by DDD.
Degenerative Disc Disease Overview
Degenerative Disc Disease (DDD) is a condition where the intervertebral discs—cushion-like structures between the spine’s vertebrae—gradually lose hydration, flexibility, and height due to aging or wear and tear. This degeneration can lead to pain, stiffness, reduced mobility, and sometimes nerve compression, causing symptoms like numbness or weakness in the limbs. DDD most commonly affects the cervical (neck) and lumbar (lower back) spine. It is not technically a disease but a natural part of aging for many people. Treatment options include physical therapy, pain management, lifestyle changes, and in severe cases, surgical intervention like spinal fusion or disc replacement.
Get a Free Sample PDF Report to know more about Degenerative Disc Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/degenerative-disc-disease-pipeline-insight
Emerging Degenerative Disc Disease Drugs Under Different Phases of Clinical Development Include:
SB-01: Spine BioPharma, Inc.
BRTX-100: BioRestorative Therapies
Rexlemestrocel-L: Mesoblast, Ltd.
Lorecivivint: Biosplice Therapeutics
CWT 002: Causeway Therapeutics
AMG0103: AnGes, Inc.
IDCT: DiscGenics
KUR 113: Kuros Biosciences
AGA111: Angitia Biopharmaceuticals
Degenerative Disc Disease Route of Administration
Degenerative Disc Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Degenerative Disc Disease Molecule Type
Degenerative Disc Disease Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Degenerative Disc Disease Pipeline Therapeutics Assessment
Degenerative Disc Disease Assessment by Product Type
Degenerative Disc Disease By Stage and Product Type
Degenerative Disc Disease Assessment by Route of Administration
Degenerative Disc Disease By Stage and Route of Administration
Degenerative Disc Disease Assessment by Molecule Type
Degenerative Disc Disease by Stage and Molecule Type
DelveInsight’s Degenerative Disc Disease Report covers around 15+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Degenerative Disc Disease product details are provided in the report. Download the Degenerative Disc Disease pipeline report to learn more about the emerging Degenerative Disc Disease therapies
Some of the key companies in the Degenerative Disc Disease Therapeutics Market include:
Key companies developing therapies for Degenerative Disc Disease are – Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., Biosplice Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., Spine BioPharma, Inc., Angitia Biopharmaceuticals, Notogen, AnGes, Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, and others.
Degenerative Disc Disease Pipeline Analysis:
The Degenerative Disc Disease pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Degenerative Disc Disease with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Degenerative Disc Disease Treatment.
Degenerative Disc Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Degenerative Disc Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Degenerative Disc Disease market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Degenerative Disc Disease drugs and therapies
Degenerative Disc Disease Pipeline Market Drivers
Increase in the prevalence of Degenerative Disc Disease, increasing Research and Development activities are some of the important factors that are fueling the Degenerative Disc Disease Market.
Degenerative Disc Disease Pipeline Market Barriers
However, cost associated with the treatment, poor patient compliance and other factors are creating obstacles in the Degenerative Disc Disease Market growth.
Scope of Degenerative Disc Disease Pipeline Drug Insight
Coverage: Global
Key Degenerative Disc Disease Companies: Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia Biopharmaceuticals, and others
Key Degenerative Disc Disease Therapies: SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and others
Degenerative Disc Disease Therapeutic Assessment: Degenerative Disc Disease current marketed and Degenerative Disc Disease emerging therapies
Degenerative Disc Disease Market Dynamics: Degenerative Disc Disease market drivers and Degenerative Disc Disease market barriers
Request for Sample PDF Report for Degenerative Disc Disease Pipeline Assessment and clinical trials
Table of Contents
1. Degenerative Disc Disease Report Introduction
2. Degenerative Disc Disease Executive Summary
3. Degenerative Disc Disease Overview
4. Degenerative Disc Disease- Analytical Perspective In-depth Commercial Assessment
5. Degenerative Disc Disease Pipeline Therapeutics
6. Degenerative Disc Disease Late Stage Products (Phase II/III)
7. Degenerative Disc Disease Mid Stage Products (Phase II)
8. Degenerative Disc Disease Early Stage Products (Phase I)
9. Degenerative Disc Disease Preclinical Stage Products
10. Degenerative Disc Disease Therapeutics Assessment
11. Degenerative Disc Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Degenerative Disc Disease Key Companies
14. Degenerative Disc Disease Key Products
15. Degenerative Disc Disease Unmet Needs
16 . Degenerative Disc Disease Market Drivers and Barriers
17. Degenerative Disc Disease Future Perspectives and Conclusion
18. Degenerative Disc Disease Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/
